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Chapter 1
Statistical Model Checking of Membrane
Systems with Peripheral Proteins:
Quantifying the Role of Estrogen in Cellular
Mitosis and DNA Damage
Matteo Cavaliere1, Tommaso Mazza2 and Sean Sedwards3
Abstract Systems biology is a natural application of membrane systems, allowing
the analysis of biological systems using the formal technique of model checking.
To overcome the intractable model size of typical biological systems, statistical
model checking may be used to efficiently estimate the probability of properties of
interest with arbitrary levels of confidence. In this chapter we analyse a biological
system linked to breast cancer, using statistical model checking (SMC) applied to
membrane systems. To do this, we have constructed a computational platform that
integrates an SMC library with a stochastic simulator of membrane systems with
peripheral proteins. We present the methodology to investigate the role of estrogen
in cellular mitosis and DNA damage and we use our statistical model checker to
find the most appropriate time-dependent dosage of antagonist that should be used
to minimize the uncontrolled replication of abnormal cells.
1.1 Membrane Systems with Peripheral Proteins
Membrane systems are models of computation inspired by the structure and func-
tion of biological cells. The model was introduced in 1998 by Gh. Pa˘un and since
then many classes of membrane systems have been introduced and studied, with
mathematical, computer science and biological motivations. An introductory guide
to the field can be found in the recent handbook [1], while a review of applications
of membrane computing to biology can be found in [2].
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According to the original definition [3], membrane systems comprise an hier-
archical nesting of membranes that enclose regions (representing the the cellular
structure), in which free-floating objects (representing molecules) exist. Each re-
gion can have associated rules, called evolution rules, for evolving the free-floating
objects and modelling the biochemical reactions present in cellular compartments.
Rules also exist for moving objects in a synchronized manners across membranes,
symport and antiport rules, modelling cellular transport and more general commu-
nication rules [1].
In brane calculi, presented in [4], several operations (pino, exo, phago, mate, drip,
bud) explicitly involving membranes with embedded proteins are considered and
formalised in the framework of process calculi. An important difference between
brane calculi and membrane computing is that with brane calculi the evolution of
the system takes place on the membranes and not inside the compartments delim-
ited by them. In [5] the operations of brane calculi are represented in the membrane
computing framework and then studied by using tools from formal language theory.
In [6] some of the membrane operations (pinocytosis and dripping) are considered
in combination with the presence of free-floating objects and objects attached to the
membranes, while in [7] objects (peripheral proteins) are attached to either side of a
membrane, explicitly considering the inner and outer membrane surfaces. The mo-
tivation for this last model is to represent the cellular processes that are controlled
by the presence of specific proteins on the appropriate side of and integral to the
membrane: there is a constant interaction between floating chemicals and embed-
ded proteins and between peripheral and integral proteins [8]. Essential receptor-
mediated processes, such as endocytosis and signalling, are crucial to cell function
and by definition are critically dependent on the presence of peripheral and integral
membrane proteins.
The key features of the model considered in [7] are that in each region of the
system there are floating objects (the floating chemicals) and, in addition, objects
can be associated to each side of a membrane or integral to the membrane (the pe-
ripheral and integral membrane proteins). Systems constructed using this model can
perform the following operations: (i) the floating objects can be processed/changed
inside the regions of the system (emulating biochemical reactions) and (ii) the float-
ing and attached objects can be processed/changed when they interact (modelling
the interactions of the floating molecules with membrane proteins). A possible use
of the model to study biological processes is shown in [9, 7], while related models
are discussed in [10] and [11], where also the computational aspects are presented.
The use of a formal computational model such as membrane systems can be
helpful for two reasons: to facilitate the implementation of an executable specifica-
tion and allows the use of automatic methods to analyse and to discover features
concerning the dynamics of the complex cellular systems, providing in this way
algorithms that can mimic biological phenomena, [12].
In this book chapter we approach this second possibility by presenting model
checking, an algorithmic technique to formally verify the performance of a system
with respect to a property. The system is represented in a language with formal se-
mantics (in our case, multiset rewriting) and the property is expressed in temporal
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logics (e.g., linear temporal logic, LTL, and computation tree logic, CTL). The out-
put of standard model checking algorithms for these logics is Boolean: the model
either satisfies the property or it does not. Such algorithms have polynomial time
complexity with respect to the size of the model, but this is generally exponentially
related to the description of the model (i.e., the number of interacting components).
See [13] for a recent historical overview of standard model checking techniques and
[14] for comprehensive coverage.
Many real systems are modelled using some form of non-determinism to ac-
count for unknown interactions and environments. In particular, chemical systems
are often modelled with the implicit assumption that molecules move randomly,
with probabilities of interaction proportional to the total number of molecules (so-
called mass action [15]). When non-determinism is expressed with probabilities, it
is possible to quantify the probability of a property using probabilistic model check-
ing [16], which uses probabilistic or stochastic temporal logics (e.g. probabilistic
computaion tree logic, PCTL, and continuous stochastic logic, CSL) and numerical
techniques to calculate the probability of a property. Probabilistic model-checking
algorithms use the standard model checking algorithms to evaluate whether a for-
mula is satisfied in a particular state, but incur additional computational cost (poly-
nomial w.r.t. the model) to calculate the probability of being in the state. Although
techniques and data structures exist to minimise the model [14, 16, 13], in the ma-
jority of real applications (especially biological applications) the model remains
intractable. Notable successes of standard and probabilistic model checking applied
to simplified biological systems include [17, 12, 18, 19]. In particular, in [17] the
authors have shown the use of probabilistic model checking for the analysis of the
cell cycle in eukaryotes, using a modelling language based on membrane systems
and process algebra. Platforms based on membrane systems including model check-
ing have been previously implemented, [20]. A review of the probabilistic models
in membrane systems can be found in [1].
To overcome the state space explosion problem that afflicts most biological mod-
els, in this chapter we employ statistical model checking (SMC), which is an effi-
cient, approximative, variety of probabilistic model checking. SMC has been ap-
plied to biology before (e.g., [21]), but here we present the first SMC investigation
of a biological system using a membrane systems model that explicitly considers the
role of membrane proteins. To achieve this, we present the first self-contained sta-
tistical model checker dedicated to membrane systems with peripheral and integral
proteins.
There are important differences between probabilistic and statistical model check-
ing. The characteristic feature of a statistical model checker is that it estimates the
probability of a property by verifying the property against multiple independent
executions (simulations) of the system. The confidence of the estimate can be guar-
anteed to arbitrary levels of confidence by standard statistical bounds (e.g. the Cher-
noff bound [22]) and in this way SMC trades certainty for tractability. In compar-
ison to standard and probabilistic model checking, SMC does not require a finite
state space, does not require decidable logics and is less strict about how the system
is defined. Importantly, SMC is often significantly more efficient than probabilistic
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model checking for a given level of precision. Fig. 1.1 compares the performance
of probabilistic with statistical model checking applied to increasing size models
of the probabilistic dining philosophers protocol, considering the property that if a
philosopher is hungry, he will eventually be fed. The figure shows that the numerical
model checker [23] scales exponentially with increasing numbers of philosophers
(i.e., polynomially w.r.t. a model that increases exponentially), while the statistical
model checker [24] scales linearly (proportional to the length of the property).
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Fig. 1.1 Typical performance of probabilistic and statistical model checking applied to models of
the probabilistic dining philosophers protocol.
Further details of our SMC methodology are given in Section 1.2.1.
1.1.1 Formal Language Preliminaries
Membrane systems are based on formal language theory and multiset rewriting [25].
In this section we recall the theoretical notions and notations necessary in this chap-
ter.
Given the set A we denote by |A| its cardinality and by ∅ the empty set. We
denote by N and by R the set of natural and real numbers, respectively.
As usual, an alphabet V is a finite set of symbols. By V ∗ we denote the set of all
strings over V . By V+ we denote the set of all strings over V excluding the empty
string. The empty string is denoted by λ . The length of a string v is denoted by |v|.
The concatenation of two strings u,v ∈V ∗ is written uv.
The number of occurrences of the symbol a in the string w is denoted by |w|a.
A multiset is a set where each element may have a multiplicity. Formally, a mul-
tiset over a set V is a map M : V → N, where M(a) denotes the multiplicity of the
symbol a ∈V in the multiset M.
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For multisets M and M′ over V , we say that M is included in M′ if M(a)≤M′(a)
for all a∈V . Every multiset includes the empty multiset, defined as M where M(a)=
0 for all a ∈V .
The sum of multisets M and M′ over V is written as the multiset (M+M′), defined
by (M+M′)(a) = M(a)+M′(a) for all a ∈ V . The difference between M and M′
is written as (M−M′) and defined by (M−M′)(a) = max{0,M(a)−M′(a)} for all
a∈V . We also say that (M+M′) is obtained by adding M to M′ (or vice versa) while
(M−M′) is obtained by removing M′ from M. For example, given the multisets M =
{a,b,b,b} and M′ = {b,b}, we can say that M′ is included in M, that (M+M′) =
{a,b,b,b,b,b} and that (M−M′) = {a,b}.
If the set V is finite, e.g. V = {a1, . . . ,an}, then the multiset M can be explicitly
described as {(a1,M(a1)),(a2,M(a2)), . . . ,(an,M(an))}. The support of a multiset
M is defined as the set supp(M) = {a ∈V |M(a)> 0}. A multiset is empty (hence
finite) when its support is empty (also finite).
A compact string notation can be used for finite multisets: if M = {(a1,M(a1)),
(a2,M(a2)), . . . ,(an,M(an))} is a multiset of finite support, then the string w =
aM(a1)1 a
M(a2)
2 . . .a
M(an)
n (and all its permutations) precisely identify the symbols in
M and their multiplicities. Hence, given a string w ∈V ∗, we can say that it identifies
a finite multiset over V , written as M(w), where M(w) = {a ∈ V | (a, |w|a)}. For
instance, the string bab represents the multiset M(w) = {(a,1),(b,2)}, that is the
multiset {a,b,b}. The empty multiset is represented by the empty string λ .
1.1.2 Membrane Systems with Peripheral and Integral Proteins
Formal language theory can be used to provide a mathematical abstraction for the
bidirectional interactions of floating molecules with cell membranes: biochemical
rules and interactions between peripheral proteins and membranes can be formalised
in terms of multiset rewriting rules.
In this section we introduce the main notions for membrane systems with periph-
eral and integral proteins.
As it is usual in the membrane systems field, a membrane is represented by a
pair of square brackets, [ ]. A membrane structure is an hierarchical nesting of
membranes enclosed by a main membrane called the root membrane. A label is
associated to each membrane and it is written as a superscript of the membrane, e.g.
[ ]1. If a membrane has the label i we call it membrane i. Each membrane is identi-
fied by a unique label in an unique manner (there are no membranes with the same
label).
A membrane structure is essentially that of a tree data structure, where the nodes
are the membranes and the arcs represent the containment relation. Being a tree,
a membrane structure can be represented by a string of matching square brackets,
e.g., [ [ [ ]2 ]1 [ ]3 ]0.
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To each membrane there are associated three multisets, u, v and x over V , denoted
by [ ]u|v|x, where V denotes a finite alphabet of objects (the symbol | is not part of
the alphabet V ).
Following the terminology used in [9] we say that the membrane is marked by
u, v and x; x is called the external marking, u the internal marking and v the in-
tegral marking of the membrane. In general, we refer to them as markings of the
membrane.
The internal, external and integral markings of a membrane model the proteins
attached to the internal surface, to the external surface and integral to the membrane,
respectively.
In a membrane structure, the region between membrane i and any enclosed mem-
branes is called region i. To each region is associated a multiset of objects w called
the free objects of the region. The free objects are written between the brackets en-
closing the regions, e.g., [ aa [ bb ]1 ]0. The free objects of a membrane model the
floating chemicals within the regions of a cell.
We denote by int(i), ext(i) and itgl(i) the internal, external and integral markings
of membrane i, respectively. By f ree(i) we denote the free objects of region i. For
any membrane i, distinct from a root membrane, we denote by out(i) the label of
the membrane enclosing membrane i. The finite set of all possible labels is denoted
by Lab.
The string
[ ab [ cc ]2a| | [ abb ]
1
bba|ab|c ]
0
represents, for instance, a membrane structure, where to each membrane are associ-
ated markings and to each region are associated free objects. Membrane 1 is inter-
nally marked by bba (i.e., int(1) = bba), has integral marking ab (i.e., itgl(1) = ab)
and is externally marked by c (i.e., ext(1) = c). To region 1 are associated the free
objects abb (i.e., f ree(1) = abb). To region 0 are associated the free objects ab. Fi-
nally, out(1) = out(2) = 0. Membrane 0 is the root membrane. The string can also
be depicted diagrammatically, as in Fig. 1.2.
Fig. 1.2 Graphical representation of [ ab [ cc ]2a| | [ abb ]
1
bba|ab|c ]
0
As in [9] we consider the rules attachin, attachout , de-attachin and de-attachout ,
defined in the following manner:
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attachin : [ α ]iu|v| → [ ]iu′|v′| , α ∈V+,u,v,u′,v′ ∈V ∗, i ∈ Lab
attachout : [ ]i|v|x α → [ ]i|v′|x′ , α ∈V+,v,x,v′,x′ ∈V ∗, i ∈ Lab
de-attachin : [ ]iu|v| → [ α ]iu′|v′| , α,u′,v′,u,v ∈V ∗, |uv|> 0, i ∈ Lab
de-attachout : [ ]i|v|x→ [ ]i|v′|x′α, α,v′,x′,v,x ∈V ∗, |vx|> 0, i ∈ Lab
Using the notion of multiset presented earlier, we describe the formal semantics of
the rules.
The attachin rule is applicable to membrane i if f ree(i) includes α , int(i) in-
cludes u and itgl(i) includes v. When the rule is applied to membrane i, α is re-
moved from f ree(i), u is removed from int(i), v is removed from itgl(i), u′ is added
to int(i) and v′ is added to itgl(i). The objects not involved in the application of the
rule are left unchanged in their original positions.
The attachout rule is applicable to membrane i if f ree(out(i)) includes α , itgl(i)
includes v, ext(i) includes x. When the rule is applied to membrane i, α is removed
from f ree(out(i)), v is removed from itgl(i), x is removed from ext(i), v′ is added
to itgl(i) and x′ is added to ext(i). The objects not involved in the application of the
rule are left unchanged in their original positions.
The de-attachin rule is applicable to membrane i if int(i) includes u and itgl(i)
includes v. When the rule is applied to membrane i, u is removed from int(i), v is
removed from itgl(i), u′ is added to int(i), v′ is added to itgl(i) and α is added to
f ree(i). The objects not involved in the application of the rule are left unchanged in
their original positions.
The de-attachout rule is applicable to membrane i if itgl(i) includes v and ext(i)
includes x. When the rule is applied to membrane i, v is removed from itgl(i), x
is removed from ext(i), v′ is added to itgl(i), x′ is added to ext(i) and α is added
to f ree(out(i)). The objects not involved in the application of the rule are left un-
changed in their original positions.
Instances of attachin, attachout , de-attachin and de-attachout rules are depicted
in Fig. 1.3.
Extending the model in [9], we also consider rules that model the shuttling and
translocation of proteins across membranes, as those considered in [10] and [11]. In
this case, floating objects can cross membranes depending on the proteins present
on the membrane (proteins may also change during the translocation).
shuttleout : [ α ]iu|v| → [ ]iu′|v′| α, α ∈V+,u,v,u′,v′ ∈V ∗, i ∈ Lab
shuttlein : [ ]i|v|x α → [ α]i|v′|x′ , α ∈V+,v,x,v′,x′ ∈V ∗, i ∈ Lab
The operation of translocation and shuttling can be envisaged as an instantaneous
combination of attach and de-attach rules described above. The shuttlein rule is
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attachin rule [ b ]ib|c|→ [ ]idb|c| attachout rule [ ]i|c|a b→ [ ]i|c|ad
de-attachin rule [ ]ibb|c|→ [ d ]ib|c| de-attachout rule [ ]i|c|a→ [ ]i| |a d
Fig. 1.3 Examples of attachin, attachout , de-attachin and de-attachout rules, showing how free and
attached objects may be rewritten. For example, in the attachin rule one of the two free instances
of b is rewritten to d and added to the membrane’s internal marking.
applicable to membrane i if itgl(i) includes v, ext(i) includes x and f ree(out(i))
includes α . When the rule is applied to membrane i, v is removed from itgl(i), x is
removed from ext(i), v′ is added to itgl(i), x′ is added to ext(i) and α is added to
f ree(i). The objects not involved in the application of the rule are left unchanged in
their original positions.
The shuttleout rule is applicable to membrane i if itgl(i) includes v, int(i) includes
u and f ree(i) includes α . When the rule is applied to membrane i, v is removed from
itgl(i), u is removed from int(i), v′ is added to itgl(i), u′ is added to int(i) and α is
added to f ree(out(i)). The objects not involved in the application of the rule are left
unchanged in their original positions.
shuttlein rule b[ ]i|c| → [ b]i|c| shuttleout rule [ b]i|c| → [ ]i|c| b
Fig. 1.4 Examples of shuttlein and shuttleout rules, showing how free objects can cross membranes
with the help of peripheral and integral proteins.
We denote by RattV,Lab the set of all possible attach, de-attach and shuttle rules
over the alphabet V and set of labels Lab.
As in [9], we also consider evolution rules that replace the free objects contained
in a region conditional on the markings of the enclosing membrane. These rules
represent the biochemical reactions that take place within the cytoplasm of a cell.
An evolution rule has the following syntax:
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evol : [ α → β ]iu|v|
where u,v,β ∈V ∗, α ∈V+, and i ∈ Lab.
The semantics of the rule is as follows. The rule is applicable to region i if f ree(i)
includes α , int(i) includes u and itgl(i) includes v. When the rule is applied to region
i, α is removed from f ree(i) and β is added to f ree(i). The membrane markings
and the objects not involved in the application of the rule are left unchanged in their
original positions.
We denote by RevV,Lab the set of all evolution rules over the alphabet V and set of
labels Lab. An instance of an evolution rule is represented in Fig. 1.5.
Fig. 1.5 evol rule [ a→ b ]ib|c|. Free objects can be rewritten inside the region and the rewriting can
depend on the integral and internal markings of the enclosing membrane.
In general, when a rule has label i we say that a rule is associated to membrane i
(in the case of attach and de-attach rules) or is associated to region i (in the case of
evol rules). For instance, in Fig. 1.3 the attachin is associated to membrane i.
The objects of α , u and v for attachin/evol rules, of α , v and x for attachout rules,
of u and v for de-attachin rules and of v and x for de-attachout rules are the reactants
of the corresponding rules. E.g., in the attach rule [ b ]a|c| → [ ]d|c| , the reactants are
a, b and c.
A membrane system with peripheral and integral protein is a mathematical model
that considers membranes to which can be associated peripheral proteins, integral
proteins, free objects and using the operations described above. The rules presented
here can be implemented in the computational tool using the appropriate syntax
[26], and present redundancies whose purpose is to allow flexibility during the mod-
elling processes. Several specific restricted variants of the proposed rules have been
investigated and a review can be found in [10].
Here, following [9], we consider the stochastic extension of the model.
Definition 1. A stochastic membrane system with peripheral and integral proteins
and n membranes is a construct
Π = (VΠ ,µΠ ,(u0 ,v0 ,x0)Π , . . . ,(un−1,vn−1,xn−1)Π ,w0,Π , . . . ,wn−1,Π ,RΠ ,
tin,Π , t f in,Π , rateΠ )
• VΠ is a non-empty alphabet of objects.
• µΠ is a membrane structure with n≥ 1 membranes injectively labelled by labels
in LabΠ = {0,1, · · · ,n−1}, where 0 is the label of the root membrane.
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• (u0,v0,x0)Π = (λ ,λ ,λ ),(u1 ,v1 ,x1)Π , · · · ,(un−1,vn−1,xn−1)Π ∈V ∗×V ∗×V ∗ are
called initial markings of the membranes.
• w0,Π ,w1,Π , · · · ,wn−1,Π ∈V ∗ are called initial free objects of the regions.
• RΠ ⊆ RattV,LabΠ−{0} ∪R
ev
V,LabΠ
is a finite set of evolution rules, attach/de-attach
and shuttle rules.
• tin,Π , t f in,Π ∈ R are called the initial time and the final time, respectively.
• rateΠ : RΠ 7−→ R is the rate mapping. It associates to each rule a reaction rate.
An instantaneous description I of Π consists of the membrane structure µΠ with
markings associated to the membranes and free objects associated to the regions. We
denote by I(Π) the set of all instantaneous descriptions of Π . We say membrane
(region) i of I to denote the membrane (region, respectively) i present in I.
Let I be an arbitrary instantaneous description from I(Π) and r an arbitrary rule
from RΠ . Suppose that r is associated to membrane i ∈ LabΠ if r ∈RattV,LabΠ−{0} (or
to region i ∈ LabΠ if r ∈RevV,LabΠ ).
If r is applicable to membrane i (or to region i, accordingly) of I, then we say
that r is applicable to I. We denote by r(I) ∈ I(Π) the instantaneous description of
Π obtained when the rule r is applied to membrane i (or to region i, accordingly) of
I (in short, we say r is applied to I).
The initial instantaneous description of Π , Iin,Π ∈ I(Π), consists of the mem-
brane structure µΠ with membrane i marked by (ui,vi,xi)Π for all i ∈ LabΠ −{0}
and free objects wi,Π associated to region i for all i ∈ LabΠ .
A configuration of Π is a pair (I, t) where I ∈ I(Π) and t ∈R; t is called the time
of the configuration. We denote by C (Π) the set of all configurations of Π . The
initial configuration of Π is Cin,Π = (Iin,Π , tin,Π ).
Suppose that RΠ = {rule1,rule2, . . . ,rulem} and let S be an arbitrary sequence
of configurations
〈C0,C1, · · · ,C j,C j+1, · · · ,Ch〉, where C j = (I j, t j) ∈ C (Π) for 0 ≤ j ≤ h. Let a j =
m
∑
i=1
pij, 0≤ j ≤ h, where pij is the product of rate(rulei) and the mass action combi-
natorial factor [27] for rulei and I j.
The sequence S is an evolution of Π if
• for j = 0, C j =Cin,Π
• for 0≤ j ≤ h−1, a j > 0, C j+1 = (r j(I j), t j +dt j) with r j, dt j as in [27]:
– r j = rulek, k ∈ {1, · · · ,m} and k satisfies
k−1
∑
i=1
pij < ran
′
j ·a j ≤
k
∑
i=1
pij
– dt j = (−1/a j)ln(ran′′j)
where ran
′
j,ran
′′
j are two random variables over the sample space (0,1], uni-
formly distributed.
• for j = h, a j = 0 or t j ≥ t f in,Π .
In other words, an evolution of Π is a sequence of configurations
〈C0,C1, · · · ,C j,C j+1, · · · ,Ch〉, starting from the initial configuration of Π , where,
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given the current configuration C j = (I j, t j), the next one C j+1 = (I j+1, t j+1), is ob-
tained by applying the rule r j to the current instantaneous description I j and adding
dt j to the current time t j. The rule r j and the associated dt j are determined by
Gillespie’s theory of chemically reacting systems [15] applied to the current in-
stantaneous description I j (i.e., effectively, the rule with the shortest waiting time is
selected to be executed). The evolution of the system halts when all rules have prob-
ability zero to be executed (following from the fact that a j = 0) or when the current
time is greater or equal to the specified final time. The detailed explanation of the ap-
plication of Gillespie’s stochastic simulation algorithm [15] to a membrane system
with peripheral proteins can be found in [9] and [28]. Similar implementations of the
Gillespie algorithm have been already proposed in different models of membrane
systems where the algorithm has been specifically adapted and optimized to run in
multiple compartments and, for these reasons, referred to as multi-compartment in
[17] and [20].
1.2 Statistical Model Checking for Membrane Systems with
Peripheral Proteins
A stochastic membrane system with peripheral proteins can capture the essential dy-
namics of a cellular system. It may be used to address questions concerning the in-
terplay between the biochemical processes present in the various compartments and
the proteins associated to the cellular membranes. Sometimes, these questions can
be resolved in an analytical manner [29] or by executing the model on a computer,
[9, 30, 28]. In this chapter we use this latter approach (for an analytical approach
see the review [10]). As defined in Section 1.1.2, a single evolution of the system
produces an outcome that represents the quantities of the involved entities, floating
molecules, peripheral proteins and compartments. However, because of the stochas-
tic applications of the rules, each evolution of the system may lead to (a possibly
very large number of) different outcomes.
In what follows, we describe the use of statistical model checking to investigate
biological systems, where properties of interest are specified using temporal logic.
1.2.1 Temporal logic as a query language
Many useful properties of systems can be expressed in terms of maxima, minima or
averages of system variables. With more complex reactive systems, such as biolog-
ical systems, it is often desirable to investigate properties that comprise sequences
of events and events dependent on time. Temporal logic provides a formal means to
express these properties and remains reasonably intuitive for moderately complex
properties. In this chapter we use temporal logic as a query language to investi-
gate temporal properties of a biological system. We have developed a statistical
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model checker based on the logic of PLASMA [24]. This logic is also similar to the
bounded linear temporal logic (BLTL) of [21]. Specifically, we have constructed a
tool using PLASMA-lab [31, 32], a statistical model checking library that works
with an external simulator. We have thus created a simulator that implements a lan-
guage of stochastic membrane systems with peripheral and integral proteins [33].
For the purposes of exposition, a logical property φ of our model checker is
constructed using the following abstract syntax:
φ = φ ∨φ | φ ∧φ | ¬φ | F≤bφ | G≤bφ | φ U≤bφ | Xφ | α
α = numeric(> |≥|= |≤|<)numeric
∨,∧ and ¬ are the standard logical connectives or, and and not. α is an atomic
proposition constructed from numeric expressions of constants and system variables
using the standard relational operators. X is the next temporal operator (Xφ is true
iff φ is true on the next step). F, G and U are temporal operators bounded by a
closed interval [0,b], where b may refer to steps or time. We use the notation φt and
ψt to denote the value of the propositions φ and ψ at step or time t. F is the finally
or eventually operator (F≤bφ is true iff ∃t ∈ [0,b] : φt is true). G is the globally
or always operator (G≤bφ is true iff ∀t ∈ [0,b] : φt is true). U is the until operator
(ψU≤bφ is true iff ∃t ∈ [0,b] : φt is true ∧(t = 0∨∀t ′ ∈ [0, t[: ψt ′ is true). In the
case of nested temporal operators, the time bound of an inner temporal operator is
relative to the time bound of its directly enclosing operator. Hence, e.g., F≤3G≤4φ
is true iff ∃t ∈ [0,3],∀t ′ ∈ [t, t+4] : φt ′ is true.
Statistical model checking works by verifying a property φ against N ∈ N in-
dependent simulation runs. Each simulation run evaluates to true or false and the
probability that φ is true on an arbitrary execution of the system is estimated by
the standard Monte Carlo estimator 1N ∑
N
i=1 1(φ), where 1(·) is an indicator function
that returns 1 if its argument is true and 0 otherwise. To quantify the confidence of
the estimate, in this chapter we use a Chernoff bound [22] that guarantees, for given
N, that the absolute error of the estimate is less than ε with probability δ , where
2εN = ln(2/δ ).
1.3 A Case Study: The Role of Estrogen in Cellular Mitosis and
DNA Damage
At a cellular level, life is punctuated by the recurrence of four major phases: Gap 1
(G1), S, Gap 2 (G2), and M. G1 is in between mitosis and DNA replication and
is responsible for cell growth. The transition occurring at the restriction point (called
R) during the G1 phase commits a cell to the proliferative cycle. If the conditions
that enforce this transition are not present, the cell exits the cell cycle and enters a
non-proliferative phase (called G0) during which cell growth, segregation and apop-
tosis occur. Replication of DNA takes place during the synthesis phase (called S). It
is followed by a second gap phase responsible for cell growth and preparation for di-
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vision. Mitosis and production of two daughter cells occur in the M phase. Switches
from one phase to another are canonically regulated by a family of Cyclins that
act as regulatory subunits for the Cyclin-Dependent Kinases (CDKs). According to
the actual phase of the cell cycle, a disparate number of chemicals interact with
the Cyclin-CDKs complexes to prevent or favour their move into the nucleus and,
consequently, to block or promote the next phase transition [34].
Here we focus on the pre-mitotis G2 phase and model the contention on the
Mitosis Promoting Factor (MPF) (i.e., the Cyclin B1/2-CDKs complex), after the
occurrence of DNA damage, by two key contributors: p53, the ”guardian of the
genome” [35], and the estrogens. The predominance of one’s function over the other
results in a proliferative rather than in a quiescent state of the cell.
It is known that p53 is a crucial protein in multicellular organisms, where it regu-
lates the cell cycle and functions as a tumour suppressor. p53 has many mechanisms
of anticancer function. It can (i) activate DNA repair proteins when DNA has sus-
tained damage; (ii) induce growth arrest by holding the cell cycle at the G1/S reg-
ulation point on DNA damage recognition; (iii) initiate apoptosis, the programmed
cell death, if DNA damage proves to be irreparable. In G2 phase and after DNA
damage, activated p53 binds DNA and induces expression of 14-3-3-σ (a.k.a. Strat-
ifin) [36]. Stratifin mRNA exits the nucleus and, after translation, obstructs cell cycle
entry by sequestering MPF, thereby preventing its shuttling to the nucleus [37].
Conversely, estrogens, the primary female sex hormones, promote cell cycle pro-
gression. They are intracellular proteins present both on the cell surface membrane
and in the cytosol. Their actions are assumed to be mediated by estrogen receptors
(ERs) which are found in different ratios in the different tissues of the body:
• ERα : endometrium, breast cancer cells, ovarian stroma cells and hypothalamus.
• ERβ : kidney, brain, bone, heart, lungs, intestinal mucosa, prostate and endothelial
cells.
ERs actions can be selectively enhanced or disabled by some estrogen receptor
modulators, in accordance with the binding affinity level of each estrogenic com-
pound. In the classic model, the estrogen 17 beta estradiol binds to the ER, causing
displacement of chaperone proteins. Dimers of the estrogen-ER complexes can then
act as transcription factors by binding to specific estrogen response element (ERE)
sequences in the promoters of target genes, evoking a wide range of transcriptional
responses.
Efp, a RING-finger-dependent ubiquitin ligase, is a relevant target gene product
of ERα . It is predominantly expressed in various female organs and is responsi-
ble for the proteolysis of 14-3-3-σ and then it is essential for estrogen-dependent
cell proliferation. Its transcription is mediated by the estrogen-ERα complex which
enters the nucleus and binds to its ERE. The Efp mRNA can exit the nucleus, trans-
late and eventually bind to the complex stratifin-MPF, floating in the cytoplasm in
an inactive form. The newly formed complex dissociates into a macromolecule of
ubiquitinated stratifin and one active MPF complex. While the former is targeted for
death by proteolysis, the latter can enter the nucleus and promote mitosis progres-
sion.
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Fig. 1.6 SBGN diagram of the considered model.
The described pathway is collected from the Biocarta Pathway Database and
redrawn using Systems Biology Graphical Notation (SBGN) glyphs in Fig.1.6.
The described cell cycle pathway is crucial to the understanding of cancer be-
cause one of the hallmarks of cancer is the uncontrolled proliferation of abnormal
or damaged cells. The focus of many treatments is therefore to prevent cell division
(mitosis) of such cells. Estrogen is implicated in certain important types of breast
cancer (e.g., estrogen receptor positive cancer), so in this chapter we present the
methodology to study the role of estrogen in cellular mitosis, analysing the scenario
in which DNA damage occurs. Sources of damage are not discussed in depth here,
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although they are commonly ascribed to a prolonged exposure to ionizing or ultra-
violet irradiation, or to sporadic mistakes made by the mitotis machinery. In view
of this, we investigate the relationship between damage, estrogen, its receptor, and
a typical antagonist that acts to prevent mitosis.
There are many synthetic molecules on the market that play the role of antagonist
to cancer. Tamoxifen, Raloxifene and Anastrozole are some of the most represen-
tative. Their antagonism makes sense when coupled with true agonists, which are
molecules that typically bind to receptors of a cell and trigger a response by that cell.
Agonists often mimic the action of a naturally occurring substance, whereas antag-
onists block the action of the agonists or cause an action opposite to that of the ag-
onists. The current accepted definition of receptor antagonist is based on the recep-
tor occupancy model: agonists are thought to turn on a single cellular response by
binding to the receptor, thus initiating a biochemical mechanism for change within a
cell. Antagonists are thought to turn off that response by blocking the receptor from
the agonist. Whenever the action of the antagonist results to be irreversible, that is
its effect lasts throughout the lifetime of the antagonist itself, its dynamics can be
described as a key broken off in the lock that prevents any other key from being
inserted.
These antagonists are essentially prodrugs, and we have added them, in an ap-
propriate way, to the described pathway (see Fig. 1.6). In particular, Tamoxifen,
an estrogen blocker that belongs to the class of non-steroidal anti-estrogens, causes
cells to remain in the G0 and G1 phases of the cell cycle. In particular, it fights breast
cancer by competing with estrogen for space on the receptors of the tumour tissue.
Each molecule of Tamoxifen that binds to a receptor prevents an estrogen molecule
from engaging at the same place. This can facilitate the treatment of cancer because
without a continuous supply of estrogen, cancer cells do not develop and the ability
of the tumour to spread is reduced.
Recent experimental work has recognised that drug therapies may be more effec-
tive when linked to specific phases of the cell cycle [38] - so-called chronoparma-
ceuticals used in chronotherapy - so we specifically consider the time (delay) of the
damage with respect to availability of cyclins (the molecules that control mitosis).
In this chapter we propose a preliminary study on the interplay between the time of
the DNA damage, the amount of the damage and the presence of antagonists.
1.4 Methodology and Results
Using PLASMA-lab [32], we have implemented a statistical model checker that
allows us to analyse the evolutions of a stochastic membrane systems with periph-
eral proteins (defined in Section 1.1.2), specified in an appropriate syntax and using
queries expressed in temporal logic (defined in Section 1.2.1). The integrated com-
putational platform can be found at the web-page [26].
The biological model used in our investigation (discussed in Section 1.3) is de-
scribed in terms of a membrane system in Fig. 1.7, where the corresponding simu-
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lator script can also be found. In our study, we explicitly consider as parameters the
amount of damage, the delay time of the damage and the amount of antagonist. We
model the existence of damage by the production of p53, a well known indicator,
that results from a damage signal that is instantiated as a quantity of molecules de-
noted as damage. Our modelling language allows us to inject an amount of damage
at a specific time, using the syntax amount damage@delay, where “amount” is a
number of damage molecules and “delay” is the value of the time delay from the
start of the simulation. As an indicator of mitosis, we define a molecular species
denoted MITOSIS, that is produced by the cyclins in the nucleus. For the purposes
of our investigation, we set an arbitrary minimum of 300 molecules of MITOSIS
to indicate that mitosis will proceed. Our results remain qualitatively similar if this
value is changed.
To estimate the probability of mitosis we consider the following temporal logic
property:
F≤delay damage = 0∧ (X damage = amount ∧ (F≤20 MITOSIS > 300)) (1.1)
This property states that in the interval [0,delay] there will be a time when damage=
0 and in the next state damage= amount and within 20 time units MITOSIS > 300.
In our experiments, the value of delay is set to the time at which we inject damage
and amount to the amount of damage injected. Hence, the first part of the property is
guaranteed to be satisfied and is used to detect the precise step that damage occurs1.
This allows the remainder of the property to be timed relative to the damage event.
The value of 20 time units is chosen to be sufficiently long to capture all interesting
behaviour following the damage.
We performed statistical model checking on the model with our model checking
tool using the property (1.1). Fig. 1.8 illustrates the results of considering amounts of
damage in the range [300,1000] with increments of 25 and delays in the range [0,5]
with increments of 0.2. Each point is the result of 37 simulations, which is sufficient
(according to the Chernoff bound defined in Section 1.2.1) to give a confidence of
±0.1 with probability 0.95. 0.95 (95%) is a standard high level of confidence, while
±0.1 is sufficiently precise to resolve the detail in the figure. Fig. 1.9 is the result
of the same experiments, but with 1000 antagonist. The results for each figure were
generated on a single machine (Intel Core i7 2.8Ghz, 4 GB RAM) in less than an
hour. The general trends are clear in both figures: the probability of mitosis increases
with increasing delay and decreases with increasing damage; above a delay of about
4 time units, mitosis is guaranteed, independent of amount of damage. This confirms
our expectation that cell damage causes cell cycle arrest and that if the damage oc-
curs after mitosis has begun, it will be too late to have an effect. Comparing Fig. 1.8
and Fig. 1.9, we see that the addition of antagonist increases the region of the figure
where the cell cycle is arrested. In particular, the system is more sensitive to lower
amounts of damage, confirming our understanding of the effect of an antagonist. We
also note that the addition of antagonist has much less effect with respect to delay.
1 For zero delay we use the simpler property damage = amount ∧ (F≤20 MITOSIS > 300)
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Π system estr Simulator script
Vestr = {damage, p53,ERal pha estrogen,E f p, object damage, p53,ERal pha estrogen,E f p,
strati f in,CDKs Cyclin B1 2,MITOSIS, strati f in,CDKs Cyclin B1 2,MITOSIS,
estrogen,ERal pha,CDKs Cyclin B1 2 strati f in, estrogen,ERal pha,CDKs Cyclin B1 2 strati f in,
Ub ligase,CDKs Cyclin B1 2 strati f in ubiquitin, Ub ligase,CDKs Cyclin B1 2 strati f in ubiquitin,
strati f in ubiquitin } strati f in ubiquitin
rule nucleoplasm rules
{
r1 : [ damage→ p53]nucleopl| | damage→ p53
r2 : [ ]
nucleopl
| | ERal pha estrogen→ [ERal pha estrogen]nucleopl| | ||+ERal pha estrogen−> ERal pha estrogen+ ||
r3 : [ ERal pha estrogen]
nucleopl
| | → [ ]nucleopl| | ERal pha estrogen ERal pha estrogen+ || 0.3→ ||+ERal pha estrogen
r4 : [ ERal pha estrogen→ ERal pha estrogen+E f p]nucleopl| | ERal pha estrogen−> ERal pha estrogen+E f p
r5 : [ E f p]
nucleopl
| | → [ ]nucleopl| | E f p E f p+ || → ||+E f p
r6 : [ p53→ p53+ strati f in]nucleopl| | p53→ p53+ strati f in
r7 : [ strati f in]
nucleopl
| | → [ ]nucleopl| | strati f in strati f in+ ||−> ||+ strati f in
r8 : [ ]
nucleopl
| | CDKs Cyclin B1 2→ [CDKs Cyclin B1 2]nucleopl| | ||+CDKs Cyclin B1 2 0.06 →CDKs Cyclin B1 2+ ||
r9 : [CDKs Cyclin B1 2]
nucleopl
| | → [ ]nucleopl| | CDKs Cyclin B1 2 CDKs Cyclin B1 2+ || 0.03 → ||+CDKs Cyclin B1 2
r10 : [CDKs Cyclin B1 2→MITOSIS]nucleopl| | CDKs Cyclin B1 2→MITOSIS
}
rule cytoplasm rules
{
r11 : [ ]
cyto
| |ERal phaestrogen→ [ ]cyto| |ERal pha estrogen ||ERal pha+ estrogen 0.1→ ||ERal pha estrogen
r12 : [ ]
cyto
| |ERal pha estrogen→ [ ERal pha estrogen]cyto| | ||ERal pha estrogen−> ERal pha estrogen+ ||
r13 : [CDKs Cyclin B1 2+ strati f in→ CDKs Cyclin B1 2+ strati f in→
CDKs Cyclin B1 2 strati f in]cyto| | CDKs Cyclin B1 2 strati f in
r14 : [E f p+Ub ligase+CDKs Cyclin B1 2 strati f in→ E f p+Ub ligase+CDKs Cyclin B1 2 strati f in→
CDKs Cyclin B1 2 strati f in ubiquitin+Ub ligase ]cyto| | CDKs Cyclin B1 2 strati f in ubiquitin+Ub ligase
r15 : [CDKs Cyclin B1 2 strati f in ubiquitin→ CDKs Cyclin B1 2 strati f in ubiquitin→
CDKs Cyclin B1 2+ strati f in ubiquitin ]cyto| | CDKs Cyclin B1 2+ strati f in ubiquitin
r16 : [ strati f in ubiquitin→ λ ]cyto| | strati f in ubiquitin→∗
r17 : [ ]
cyto
| |ERal phaantagonist→ [ ]cyto| |ERal pha antagonist ||ERal pha+antagonist → ||ERal pha antagonist
}
µestr = [ [ ]nucleopl ]cyto compartment
nucleoplasm[1000 damage@500,nucleoplasm rules]
wcyto =CDKs Cyclin B1 21000,Ub ligase1000 compartment cytoplasm[1000 CDKs Cyclin B1 2,
wnucleopl = λ 1000 Ub ligase,nucleoplasm,
cytoplasm rules : ||1000ERal pha]
w0 = estrogen10000 system cytoplasm,10000 estrogen
(unucleopl = λ ,vnucleopl = λ ,xnucleopl = λ )
(ucyto = λ ,vcyto = λ ,xcyto = ERal pha1000)
tin = 0, t f in = 20.000 evolve 0−20000
rate(r3) = 0.3, rate(r8) = 0.06,
rate(r9) = 0.03, rate(r11) = 0.1
Fig. 1.7 A stochastic membrane systems with peripheral and integral proteins that presents the
P53-independent G2/M cell cycle arrest pathway, with data collected from the Biocarta Pathways
Database, described in Fig. 1.6 and ranges of proportionality between the coefficients obtained
using preliminary western-blotting experiments. On the left side we present the formal language
model following the formal syntax presented in Section 1.1.2 (the membrane labels cyto and nucle-
opl stands for cytoplasm and nucleoplasm, respectively); on the right side the equivalent simulator
script using the appropriate syntax. The complete description of the simulator syntax can be found
in [28], [9] and at the platform webpage [26].
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Having observed that the presence of antagonist increases the sensitivity of the
system to damage, we investigated the amount of antagonist required to cause cell
cycle arrest. The results are plotted in Fig. 1.10 and were achieved in the follow-
ing way. We estimated the probability of mitosis, as defined by the property (1.1),
considering three parameters: amount of damage in the range [300,900] with incre-
ments of 25, delay of damage in the range [0,4] with increments of 0.2, and amount
of antagonist in the range [0,2100] with increments of 100. Thus, for each combi-
nation of amount and delay of damage, we constructed a sequence of probabilities
corresponding to the amounts of antagonist, each estimated with the same level of
confidence used for Figs. 1.8 and 1.9. The results were generated on a single ma-
chine (Intel Core i7 2.8Ghz, 4 GB RAM) in less than 14 hours. Three qualitatively
distinct sequences of probabilities emerged: (i) probabilities consistently below 0.5
for all considered values of antagonist (black area in Fig. 1.10); (ii) probabilities
consistently above 0.5 for all considered values of antagonist (yellow area marked
with ‘+’ symbols) and (iii) probabilities decreasing from values above 0.5 to values
below 0.5 with increasing antagonist. Sequences of type (i) correspond to a range of
parameters where cell cycle arrest is inevitable, regardless of antagonist. Sequences
of type (ii) correspond to a range of parameters where either mitosis is inevitable
or more than the maximum amount of antagonist that we tried is required to cause
cell cycle arrest. From sequences of type (iii) we were able to estimate the amount
of antagonist corresponding to the transition value of 0.5, by interpolating between
two adjacent points or from a single point if, by chance, its value was exactly 0.5.
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Fig. 1.8 The effect of amount and delay of damage on mitosis: the probability of MITOSIS > 300
for various amounts and time delay of damage. The figure illustrates the general trend that the
probability of mitosis increases with increasing delay and decreasing damage.
1 Statistical Model Checking of Membrane Systems with Peripheral Proteins 19
 0
 1
 2
 3
 4
 5
 300  400  500  600  700  800  900  1000
D
el
ay
 ti
m
e 
of
 d
am
ag
e
Amount of damage
 0
 0.2
 0.4
 0.6
 0.8
 1
Pr
ob
ab
ilit
y 
of
 M
IT
O
SI
S 
> 
30
0
Fig. 1.9 The effect of antagonist on the response to damage: the probability of MITOSIS > 300
for various amounts and delay of damage in the presence of 1000 antagonist. In comparison with
Fig. 1.8, the figure demonstrates that antagonist increases the sensitivity of the system to damage.
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Fig. 1.10 The required dosage of antagonist to prevent mitosis: the amount of antagonist required
to make the probability of MITOSIS > 300 less than 0.5 when previously it was greater than 0.5.
In the black areas the probability of MITOSIS > 300 is less than 0.5, independent of antagonist.
The ‘+’ symbol indicates that at least 2100 antagonist would be required to prevent mitosis.
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1.5 Conclusions
Even though the life cycle of cells is not generally synchronized, we recall here that
replication is subject to the presence of cyclins, that are released in a timely way. Our
results then show that it is possible to target cells on time, that is, to occupy estro-
gen receptors (ERs) at time points that are maximally effective. This would convey
a double advantage: minimizing the necessary quantity of antagonist and making
its effect optimal. The definition of the most effective dosage curve is indeed not a
simple task, especially in cases where antagonists cannot be specific for particular
cells. For example, in the case of ER+ breast cancer, Tamoxifen is currently taken
once or twice a day and it is usually prescribed at 20 mg for 5 years. This dosage is
due to the unavoidable ineffectiveness of the drug when reaching cells in unfavor-
able time points, as well as to the fact that Tamoxifen does not specifically target
breast cancer cells; its molecules circulate within the body and target any cell that
contains an available ER. The consequence of this is that while Tamoxifen works
as an anti-estrogen for the breast, it acts as estrogen (i.e., agonist) in the uterus and,
to a lesser extent, in the heart, blood vessels and bones. In cases like this, a tuned
chronotherapy cannot eliminate the risk of side effects, but can drastically reduce it.
The presented results show that the use of statistical model checking in membrane
systems could be helpful to individuate the appropriate time-dependent dosage of
antagonists in cancer treatments, [39].
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